Lead Product(s) : Erythromycin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Eastern Virginia Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Details : Erythromycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Fetal Membranes, Premature Rupture.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 23, 2024
Lead Product(s) : Erythromycin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Eastern Virginia Medical School
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Erythromycin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Final Approval from The USFDA for Erythromycin Tablets USP, 250 mg and 500 mg
Details : Erythromycin acts by inhibition of protein synthesis by binding to the 23S ribosomal RNA molecule in the 50S subunit of ribosomes in susceptible bacterial organisms.
Product Name : Erythromycin
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 09, 2023
Lead Product(s) : Erythromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
